Long-term survival outcomes with immune checkpoint inhibition in PD-L1 low or intermediate expressing gastroesophageal adenocarcinoma.
APA
Zhao JJ, Pietrantonio F (2026). Long-term survival outcomes with immune checkpoint inhibition in PD-L1 low or intermediate expressing gastroesophageal adenocarcinoma.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2026.02.016
MLA
Zhao JJ, et al.. "Long-term survival outcomes with immune checkpoint inhibition in PD-L1 low or intermediate expressing gastroesophageal adenocarcinoma.." Annals of oncology : official journal of the European Society for Medical Oncology, 2026.
PMID
41887944
같은 제1저자의 인용 많은 논문 (4)
- Precursor B-Cell Acute Lymphoblastic Leukemia With PICALM∶∶MLLT10 Fusion Gene Positivity:Report of One Case and Literature Review.
- Circ_0041150 inhibits proliferation of pancreatic adenocarcinoma cells by regulating triglyceride accumulation via the miR-1178-3p/AADAC axis.
- Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials.
- Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases.